DexCom Q2 2024 Adj EPS $0.43 Beats $0.39 Estimate, Sales $1.004B Miss $1.036B Estimate
Portfolio Pulse from Benzinga Newsdesk
DexCom (NASDAQ:DXCM) reported Q2 2024 adjusted EPS of $0.43, beating the estimate of $0.39. However, sales of $1.004 billion missed the $1.036 billion estimate. Sales increased by 15.23% year-over-year.

July 25, 2024 | 8:24 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
DexCom's Q2 2024 earnings per share of $0.43 beat estimates, but sales of $1.004 billion missed expectations. Sales increased by 15.23% year-over-year.
While DexCom's EPS beat expectations, the miss on sales figures could create mixed sentiment among investors. The year-over-year sales growth is a positive sign, but the shortfall in meeting sales estimates may temper enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100